Donaldson’s Post

In the rapidly evolving field of gene therapy manufacturing, speed is paramount.🚦 Our platform offers a significant speed advantage over traditional mammalian approaches, operating over five times faster in the upstream process. By utilizing plants as bioreactors, our platform allows batches to scale quickly and efficiently, significantly increasing production capacity. ▶️ Take a look at the video to see better detail on how our platform compares to the mammalian gene therapy manufacturing approach. #GeneTherapyManufacturing #PlantScience #Bioreactor #AAV

🚀 **Insight into Cell and Gene Therapy!** 🚀 Industry leaders discuss the evolving landscape of cell and gene therapy, highlighting the challenges in manufacturing and the necessity of better communication and digital tools. Key takeaways include the importance of adapting traditional processes and leveraging technology to enhance patient outcomes and navigate this multi-stakeholder environment. Stay ahead in personalized medicine by understanding these critical insights and the future of CGT! #CellAndGeneTherapy #PersonalizedMedicine #DigitalTransformation #HealthcareInnovation https://deloi.tt/3SdCd0D

AAV is the leader of gene therapy. But what are it's pros and cons? Let's break it down. Pros: - Current leader in vector-based gene therapy - Payload doesn't integrate into patient DNA (normally) - FDA-approved therapies on the market - Can target specific tissues for precise delivery Cons: - High cost of manufacturing - Small payload size - Good quality at scale is a challenge - Single dose administration due to high immunogenicity (for now) - Liver toxicity concerns (for now) I'm excited to see how recent advances in capsid design will fix these drawbacks. Anything else you'd add? Drop it in the comments. For content that breaks down the science of CGT: Check out #cgt_simplified “Created with BioRender.com” #genetherapy #aav #biotechnology

Rapid growth in cell and gene therapy (CGT) is leading scientists to consider how patient-centered treatments can be delivered uninterruptedly through a time-dependent and agile approach. Read our new BioPhorum publication by Maria Rende, PhD, MBioSci, Cell and Gene Therapy Expert, to learn the requirements of different CGT outbound supply chains. https://sar.to/jgy34 #SimplifyingProgress #InThisTogether #CellandGeneTherapy #AdvancedTherapies #CellTherapy #GeneTherapy

A Gene Therapy to Promote Cardiomyocyte Proliferation Improves Late Stage Heart Failure in Rats Researchers have developed a gene therapy that upregulates of Cdk1 and Cdk4 in heart muscle. These genes provoke cardiomyocytes into replication, and this has been shown to improve function in the context of heart failure. Here, researchers show tha... https://lnkd.in/eqJ4AWPB #BioTech #science

🔬 Revolutionizing gene therapy, our 𝟯𝗿𝗱 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗔𝗔𝗩 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 offers rapid insights into transgene incorporation efficiency for AAVs. Going beyond old generation methods, the 3rd Generation AAV analysis can accurately and objectively determine vector content (percentage of empty and filled particles) and distinctly identify different intermediates! The method also provides the genome length distribution of the entire AAV sample. This transformative technology delivers precise measurements, unveiling crucial details about transgene incorporation efficiency. 🚀💡 Stay at the forefront of gene therapy with our groundbreaking approach. 💪🧬 Contact info@qutem.com for more. #QuTEM #lifescience #genetherapy #innovation #aav

Highly accurate determination of the AAV vector content and genome length distribution, with our 𝟯𝗿𝗱 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗔𝗔𝗩 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀!

Learn how a publicly traded gene therapy company struggled to identify an optimal vector design to carry forward after 15 rounds of empirical optimization over three years. By applying AI/ML models, Form Bio was able to identify four optimal vector designs within days that resulted in 91% full capsids. The company was able to advance a lead and backup candidate to next steps. Explore the methods and results: https://hubs.li/Q02LwKgs0 #VectorDiscovery #AAV #GeneTherapy #InSilico

AmplifyBio is now streamlining cell & gene therapy development with Benchling. This means faster development, fewer errors, and real-time data for researchers. Read more: https://bit.ly/4au1BFn #advancedtherapies #CGT

#FastFacts now available! The evolution of #genetherapymanufacturing Here, Rachel Legmann (Senior Director of Technology, Gene Therapy, Repligen Corporation) explores how integrating process intensification by advanced technologies in both upstream and downstream production of viral vectors impacted yield of potent vectors and #vectorrecovery Read this FastFacts to learn about: ·       How to increase the number of cells producing virus with enhanced specific #viralvector productivity ·       The importance of continuous perfusion to intensified #AAV and #lentivirusproduction ·       Streamlining AAV, plasmid DNA, and #mRNA titer determination using variable pathlength analytical technology Read below: